Discovery and Preclinical Evaluation of BPB-101: a Novel Triple Functional Bispecific Antibody Targeting GARP-TGF-β Complex/SLC, Free TGF-β and PD-L1

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Dec 5

PMID 39635528

Authors

Wenxin Xu

Jieying Xu

Pingcui Li

Deyu Xu

Hongjie Cheng

Huan Zheng

Li Zhang

Mengmeng Liu

Siyuan Ye

Mengshi Jiang

Wenqi Yu

Jiabing Wang

Lieming Ding

Affiliations

Soon will be listed here.

Abstract

Background: In the tumor microenvironment (TME), the transforming growth factor-β (TGF-β) and programmed cell death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1) signaling axes are complementary, nonredundant immunosuppressive signaling pathways. Studies have revealed that active TGF-β is mainly released from the glycoprotein A repetitions predominant (GARP)-TGF-β complex on the surface of activated regulatory T cells (Tregs), B cells, natural killer (NK) cells, and tumor cells. The currently available antibodies or fusion proteins that target TGF-β are limited in their abilities to simultaneously block TGF-β release and neutralize active TGF-β in the TME, thus limiting their antitumor effects.

Methods: We designed and constructed a bispecific, trifunctional antibody, namely, BPB-101, that specifically targets the GARP-TGF-β complex and/or small latent complex (SLC), active TGF-β, and PD-L1. The binding ability of BPB-101 to the different antigens was determined by ELISA, FACS, and biolayer interferometry (BLI). The blocking ability of BPB-101 to the TGF-β and PD-1/PD-L1 signaling axes was determined by reporter gene assay (RGA). The antitumor effect and biosafety of BPB-101 were determined in a transgenic mouse tumor model and cynomolgus monkeys, respectively. Stability assessments, including stability in serum, after exposure to light, after repeated freeze-thaw cycles, and after high-temperature stress tests had been completed to evaluate the stability of BPB-101.

Results: BPB-101 bound efficiently to different antigenic proteins: the GARP-TGF-β complex and/or SLC, active TGF-β, and PD-L1. Data showed that BPB-101 not only effectively inhibited the release of TGF-β from human Tregs, but also blocked both the TGF-β and PD-1/PD-L1 signaling pathways. In an MC38-hPD-L1 tumor-bearing C57BL/6-hGARP mouse model, BPB-101 at a dose of 5 mg/kg significantly inhibited tumor growth, with a complete elimination rate of 50%. Stability assessments confirmed the robustness of BPB-101. Furthermore, BPB-101 showed a favorable safety profile in nonhuman primate (NHP) toxicity studies.

Conclusion: BPB-101 is a potentially promising therapeutic candidate that may address unmet clinical needs in cancer immunotherapy, thus, BPB-101 warrants further clinical investigation.

References

Yi M, Niu M, Zhang J, Li S, Zhu S, Yan Y . Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. J Hematol Oncol. 2021; 14(1):146. PMC: 8442312. DOI: 10.1186/s13045-021-01155-6. View

Lazarova M, Steinle A . Impairment of NKG2D-Mediated Tumor Immunity by TGF-β. Front Immunol. 2019; 10:2689. PMC: 6873348. DOI: 10.3389/fimmu.2019.02689. View

Ai L, Xu A, Xu J . Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. Adv Exp Med Biol. 2020; 1248:33-59. DOI: 10.1007/978-981-15-3266-5_3. View

Gulley J, Schlom J, Barcellos-Hoff M, Wang X, Seoane J, Audhuy F . Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment. Mol Oncol. 2021; 16(11):2117-2134. PMC: 9168966. DOI: 10.1002/1878-0261.13146. View

Satoh K, Kobayashi Y, Fujimaki K, Hayashi S, Ishida S, Sugiyama D . Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells. Int Immunol. 2021; 33(8):435-446. DOI: 10.1093/intimm/dxab027. View

Abou D, Ku T, Smith-Jones P . In vivo biodistribution and accumulation of 89Zr in mice. Nucl Med Biol. 2011; 38(5):675-81. PMC: 4527328. DOI: 10.1016/j.nucmedbio.2010.12.011. View

Zhang Y, Zhang Z . The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020; 17(8):807-821. PMC: 7395159. DOI: 10.1038/s41423-020-0488-6. View

Batlle E, Massague J . Transforming Growth Factor-β Signaling in Immunity and Cancer. Immunity. 2019; 50(4):924-940. PMC: 7507121. DOI: 10.1016/j.immuni.2019.03.024. View

Malenica I, Adam J, Corgnac S, Mezquita L, Auclin E, Damei I . Integrin-α-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade. Nat Commun. 2021; 12(1):5209. PMC: 8410945. DOI: 10.1038/s41467-021-25322-y. View

10.

Li S, Liu M, Do M, Chou C, Stamatiades E, Nixon B . Cancer immunotherapy via targeted TGF-β signalling blockade in T cells. Nature. 2020; 587(7832):121-125. PMC: 8353603. DOI: 10.1038/s41586-020-2850-3. View

11.

Burvenich I, Goh Y, Guo N, Gan H, Rigopoulos A, Cao D . Radiolabelling and preclinical characterization of Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa. Eur J Nucl Med Mol Imaging. 2021; 48(10):3075-3088. DOI: 10.1007/s00259-021-05251-0. View

12.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

13.

Mitra M, Lancaster K, Adedeji A, Palanisamy G, Dave R, Zhong F . A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys. Toxicol Sci. 2020; 175(1):24-34. DOI: 10.1093/toxsci/kfaa024. View

14.

Mousset C, Hobo W, Woestenenk R, Preijers F, Dolstra H, van der Waart A . Comprehensive Phenotyping of T Cells Using Flow Cytometry. Cytometry A. 2019; 95(6):647-654. DOI: 10.1002/cyto.a.23724. View

15.

Allen E, Jabouille A, Rivera L, Lodewijckx I, Missiaen R, Steri V . Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017; 9(385). PMC: 5554432. DOI: 10.1126/scitranslmed.aak9679. View

16.

de Streel G, Bertrand C, Chalon N, Lienart S, Bricard O, Lecomte S . Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer. Nat Commun. 2020; 11(1):4545. PMC: 7486376. DOI: 10.1038/s41467-020-17811-3. View

17.

Sugiura D, Maruhashi T, Okazaki I, Shimizu K, Maeda T, Takemoto T . Restriction of PD-1 function by -PD-L1/CD80 interactions is required for optimal T cell responses. Science. 2019; 364(6440):558-566. DOI: 10.1126/science.aav7062. View

18.

Gong J, Chehrazi-Raffle A, Reddi S, Salgia R . Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018; 6(1):8. PMC: 5778665. DOI: 10.1186/s40425-018-0316-z. View

19.

Gupta A, Budhu S, Fitzgerald K, Giese R, Michel A, Holland A . Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer. Commun Biol. 2021; 4(1):1296. PMC: 8599839. DOI: 10.1038/s42003-021-02773-z. View

20.

Fajgenbaum D, June C . Cytokine Storm. N Engl J Med. 2020; 383(23):2255-2273. PMC: 7727315. DOI: 10.1056/NEJMra2026131. View